| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| D126373-5mg | 5mg | 2 | $75.90 | |
| D126373-10mg | 10mg | 2 | $129.90 | |
| D126373-50mg | 50mg | 1 | $314.90 |
| Synonyms | BDBM185674 | 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-c |
|---|---|
| Specifications & Purity | Moligand™, ≥98% |
| Biochemical and Physiological Mechanisms | The lead "switch-control" inhibitor, DCC-2036, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-res |
| Storage Temp | Store at -20°C |
| Shipped In | Ice chest + Ice pads |
| Grade | Moligand™ |
| Action Type | INHIBITOR |
| Mechanism of action | Tyrosine-protein kinase ABL inhibitor |
| ALogP | 4.9 |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504769950 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504769950 |
| IUPAC Name | 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide |
| INCHI | InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40) |
| InChi Key | WVXNSAVVKYZVOE-UHFFFAOYSA-N |
| Canonical SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
| Isomeric SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
| PubChem CID | 25066467 |
| Molecular Weight | 553.59 |
| 1. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.. Clin Cancer Res, 17 (2): (212-21). [PMID:21098337] [10.1021/op500134e] |
| 2. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP et al.. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.. Cancer Cell, 19 (4): (556-68). [PMID:21481795] [10.1021/op500134e] |
| 3. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW et al.. (2011) The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.. Cancer Res, 71 (9): (3189-95). [PMID:21505103] [10.1021/op500134e] |
| 4. Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI. (2013) Identification of potent Yes1 kinase inhibitors using a library screening approach.. Bioorg Med Chem Lett, 23 (15): (4398-403). [PMID:23787099] [10.1021/op500134e] |
| 5. Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP et al.. (2017) The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.. Mol Cancer Ther, 16 (11): (2486-2501). [PMID:28838996] [10.1021/op500134e] |
K2229072